BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Evexomostat readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Evexomostat\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05455619-9078@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Evexomostat: Phase 1/2 readout est. (NCT05455619)
DESCRIPTION:Evexomostat\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients 
 With a PI3K Alteration and HR+/Her2- Breast Cancer\nEstimated primary comp
 letion: December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/evexomostat#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05455619
URL:https://assetmemo.bio/drug/evexomostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05570253-9078@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Evexomostat: Phase 2 readout est. (NCT05570253)
DESCRIPTION:Evexomostat\, phase 2.\nStudy: A Study of SDX-7320 in Combinati
 on With Eribulin for People With Breast Cancer\nEstimated primary completi
 on: October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/eve
 xomostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05570253
URL:https://assetmemo.bio/drug/evexomostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
